论文信息 - Immunophenotyping of acute leukemias and myelodysplastic syndromes

Immunophenotyping of acute leukemias and myelodysplastic syndromes

Alberto Orfao,* Francisco Ortuno, Maria de Santiago, Antonio Lopez, and Jesus San Miguel Servicio General de Citometria, Universidad de Salamanca, Salamanca, Spain Centro de Investigacion del Cancer y Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain Servicio de Hematologia y Oncologia Medica, Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain

[1] M. Greaves,et al. Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. , 1979, Journal of immunology.

[2] A. Órfão,et al. Immunophenotypic analysis of myelodysplastic syndromes. , 2003, Haematologica.

[3] H. Zola,et al. Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification , 1986, British journal of haematology.

[4] C. Civin,et al. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. , 1987, Blood.

[5] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[6] C. Bloomfield,et al. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry , 1998, Leukemia.

[7] H Stein,et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8] M. Greaves,et al. Phenotypic heterogeneity and cellular origins of T cell malignancies. , 1981, Leukemia research.

[9] V. Deneys,et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome , 2003, Leukemia.

[10] I. Bernstein,et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) , 2002, Leukemia.

[11] A. Órfão,et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression , 2001, Leukemia.

[12] M. Borowitz,et al. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study , 1998, Leukemia.

[13] A. Órfão,et al. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. , 1991, Blood.

[14] D. Campana,et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. , 2002, Blood.

[15] M. Tallman. Monoclonal antibody therapies in leukemias. , 2002, Seminars in hematology.

[16] N. Villamor,et al. CD56 expression could be associated with monocytic differentiation in acute myeloid leukemia with t(8;21). , 2001, Haematologica.

[17] A. Órfão,et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. , 1999, Leukemia research.

[18] Attila Tárnok,et al. Clinical applications of laser scanning cytometry. , 2002, Cytometry.

[19] J. Hernández-Rivas,et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. , 1999, Haematologica.

[20] S. Raimondi,et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. , 1991, Blood.

[21] E. Paietta. Proposals for the immunological classification of acute leukemias. , 1995, Leukemia.

[22] A. Órfão,et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. , 2004, Haematologica.

[23] D. Campana. Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.

[24] A. Órfão,et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. , 2001, Blood.

[25] B. Bain,et al. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. , 2002, Clinical and laboratory haematology.

[26] A. Órfão,et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. , 1997, Blood.

[27] B. Dörken,et al. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 , 2000, Leukemia.

[28] A. Órfão,et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.

[29] N. Villamor,et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells , 2003, Leukemia.

[30] A. Órfão,et al. Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells. , 2001, Journal of biological regulators and homeostatic agents.

[31] T. Lister,et al. Terminal Transferase Enzyme Assay and Immunological Membrane Markers in the Diagnosis of Leukaemia: a Multiparameter Analysis of 300 Cases , 1980, British journal of haematology.

[32] R. Foà,et al. Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre study , 1985, British journal of haematology.

[33] A. Órfão,et al. Immunologic monitoring in adults with acute lymphoblastic leukemia , 2003, Current oncology reports.

[34] A Orfao,et al. Impact of immunophenotyping on management of acute leukemias. , 1999, Haematologica.

[35] A. Órfão,et al. Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics. , 1988, Blood.

[36] B. Dörken,et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. , 2000, Blood.

[37] A. Órfão,et al. Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.

[38] E. Reinherz,et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[39] Yvan Cornet,et al. Immunophenotypic clustering of myelodysplastic syndromes. , 2002, Blood.

[40] H. Gralnick,et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[41] A. Venditti,et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. , 2000, Blood.

[42] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[43] M. Borowitz,et al. Flow cytometry in the diagnosis of acute leukemia. , 2001, Seminars in hematology.

[44] F. Behm,et al. Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45] Norma Gutiérrez,et al. Minimal residual disease in adolescent ( older than 14 years ) and adult acute lymphoblastic leukemias : early immunophenotypic evaluation has high clinical value , 2003 .

[46] A. Orfao,et al. Aplicación de la citometría de flujo al diagnóstico y seguimiento inmunofenotípico de las leucemias agudas , 2002 .

[47] A. Órfão,et al. BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings , 2001, Leukemia.

[48] D C Arthur,et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. , 2001, Blood.

[49] M R Loken,et al. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. , 1987, Blood.

[50] R. Valenta,et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. , 2001, Blood.

[51] A. Órfão,et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. , 1995, Leukemia.

[52] L. Terstappen,et al. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. , 1990, Leukemia.

[53] M. Ames,et al. Selected pharmacologic characteristics of idarubicin and idarubicinol. , 1992, Leukemia.

[54] L. Terstappen,et al. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. , 1990, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[55] M. Borowitz,et al. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. , 1988, Blood.

[56] Myeloid-antigen expression in adult acute lymphoblastic leukemia. , 1987 .

[57] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[58] D. Catovsky,et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[59] W. Hiddemann,et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. , 2003, Haematologica.

[60] G. Janossy,et al. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. , 1980, Blood.

[61] M. Elghetany,et al. Surface marker abnormalities in myelodysplastic syndromes. , 1998, Haematologica.

[62] A. Órfão,et al. The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias , 1998 .

[63] A. Órfão,et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. , 2001, Leukemia.

[64] M. Greaves,et al. Membrane marker analysis of 'lymphoid' and myeloid blast crisis in PH1 positive (chronic myeloid) leukemia. , 1977, Haematology and blood transfusion.

[65] E. Borden,et al. Depression of interferon production after A.L.S. treatment. , 1969, Lancet.

[66] M. Greaves,et al. ACUTE LYMPHOBLASTIC LEUKÆMIA IN CHILDREN: CLASSIFICATION AND PROGNOSIS , 1977, The Lancet.

[67] B. Drénou,et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. , 2002, Blood.

[68] A. Órfão,et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. , 1999, Clinical chemistry.

[69] A. Órfão,et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL , 1999, Leukemia.

[70] A. Órfão,et al. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells. , 2001, Clinical immunology.

[71] A. Órfão,et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. , 2002, American journal of clinical pathology.

[72] M. Greaves,et al. Patterns of gene expression and the cellular origins of human leukaemias. , 1978, Biochimica et biophysica acta.

[73] F. Behm,et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. , 1992, Blood.

[74] N. Villamor,et al. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. , 2003, Haematologica.

[75] O. Haas,et al. Immunophenotype of hematologic neoplasms with a translocation t(8;21). , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[76] J. Miguel,et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia , 1995, Annals of Hematology.

[77] H. Deeg,et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.

[78] A. Órfão,et al. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification , 2000, Leukemia.

[79] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[80] C. Rudin,et al. B-cell development and maturation. , 1998, Seminars in oncology.

[81] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[82] D. Catovsky,et al. Outcome of biphenotypic acute leukemia. , 1999, Haematologica.

[83] M R Loken,et al. Quantitative Comparison of Myeloid Antigens on Five Lineages of Mature Peripheral Blood Cells , 1990, Journal of leukocyte biology.

[84] B. Lichtiger,et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome , 2001 .

[85] D. Head,et al. Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience , 1999, Leukemia.

[86] W Hiddemann,et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. , 1992, Leukemia.

[87] A. Órfão,et al. Detection of abnormalities in B‐cell differentiation pattern is a useful tool to predict relapse in precursor‐B‐ALL , 1999, British journal of haematology.